Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients with Previously Treated mCRPC By Ogkologos - April 9, 2025 556 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-921 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR Mom Gives Birth and Receives a Breast Cancer Diagnosis on the... September 23, 2020 ESMO awards its first fellowship to support digital and computational pathology September 10, 2025 Groundbreaking Trial Results Expand Treatment Options for Some People with Bladder... November 30, 2023 Second Interim Analysis Shows OS Improvement with Adjuvant Olaparib for Germline... October 12, 2022 Load more HOT NEWS Osimertinib Shows Promising Activity in Previously Untreated Patients with Metastatic NSCLC... GreaterGood Is Donating Thousands of Masks to Help Animal Shelters Stay... Higher Risk of Heart Failure Seen in Some Cancers Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline
